InvestSMART

CSL Limited (ASX:CSL)

ALERT: Price-sensitive ASX Announcement for CSL
Current share price for CSL : $123.320 -48.07 (-28.05%)+
Announcement
Release
11 Feb 2026 7:41AM
Price at Release
$171.390
Full Release
download
Summary
CSL Limited announced its half-year financial results for the period ending December 2025, reporting a NPATA of US$1.9 billion and a total revenue of US$8.3 billion, reflecting a decline from the previous period. The company faced challenges due to policy changes, restructuring costs, and impairments, resulting in a significant reduction in reported net profit. Despite these challenges, CSL expanded its share buy-back program and maintained its growth guidance for FY26, driven by strategic transformation initiatives and investments in high-priority growth opportunities. The company's various divisions showed mixed results, with CSL Behring and Seqirus experiencing declines, whereas CSL Vifor reported growth.
Key Points
  • CSL Limited reported a half-year NPATA of US$1.9 billion for the six months ended 31 December 2025.
  • Total revenue for the period was US$8.3 billion, marking a 4% decline.
  • Reported net profit after tax was US$401 million, down 81%.
  • The company's performance was affected by governmental policy changes, restructuring costs, and impairments.
  • CSL expanded its share buy-back program to US$750 million.
  • Guidance for FY26 includes expected revenue growth of 2-3% and NPATA growth of 4-7%.
  • Transformation initiatives led to achieving 60% of targeted cost savings for FY26.
  • CSL Behring revenue dropped 7%, with Ig product sales down 6%.
  • CSL Seqirus revenue was down 2%, and CSL Vifor revenue increased by 12%.
  • The company is investing in high-priority growth initiatives including a collaboration with VarmX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.